

FOR IMMEDIATE RELEASE

AMNEAL RECEIVES FDA APPROVAL FOR LORAZEPAM ORAL CONCENTRATE, USP

Hauppauge, NY (USA), June 15, 2010 – Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture Lorazepam Oral Concentrate, USP in 2 mg/ml strength effective December 23, 2009. Amneal's generic is a C-IV controlled substance and a therapeutically equivalent alternative to Lorazepam Intensol™ (a licensed trademark of Roxane Laboratories).

Lorazepam Oral Concentrate is indicated for the management of anxiety disorders or for short-term relief of anxiety symptoms or anxiety associated with depressive symptoms.

Amneal began shipping Lorazepam Oral Concentrate in the 2 mg/ml strength as a clear, flavorless liquid easily mixed with another liquid or semi-solid food on March 26, 2010. The product is packaged in a 30 ml/1 fl oz bottle with calibrated dropper, requires refrigeration and is produced in the company's fully cGMP-compliant Branchburg, NJ manufacturing facility. It is available through wholesalers-distributors as well as directly to the trade. Amneal manufactures all of its products in the USA.

“Launching Lorazepam Oral Concentrate adds yet another capability to Amneal's distribution organization - refrigerated shipping. This also offers a nice expansion to our aggressively growing liquid products portfolio, all generated from our Branchburg, NJ liquids plant.” said Jim Luce, Amneal Executive Vice President, Sales & Marketing.

Lorazepam Oral Concentrate, USP is the latest addition to Amneal's expanding portfolio of 250 products, listed in the company's on-line product catalog at www.amneal.com. Launched last year, the comprehensive web catalog is designed for easy customer and patient access to essential information, images and literature such as product outserts, labels, patient medication guides, MSDS (material safety data sheets) and high-resolution product photos.

Amneal Pharmaceuticals LLC, headquartered in Hauppauge, NY is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as “Generic's New Generation”, the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Rapid ANDA approvals and diverse product acquisitions are key to Amneal's aggressive growth strategy, as is the company's strong commitment to deep customer relationships and maximum value creation. Amneal delivers high quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com.

###

CONTACT:

Jim Luce
Executive Vice President, Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
620 Newport Center Drive, 14th Floor
Newport Beach, California 92660